Winselow Tucker, President and General Manager, Lilly India, said, “The introduction of a second brand of tirzepatide in India through our commercial agreement with Cipla furthers Lilly’s commitment to expanding access to innovative treatments for chronic conditions. Our mission — to make life better for people around the world — drives our commitment to accelerate the introduction of innovative medicines and expand access to hard-to-reach communities.”
Also Read: Cipla Q1 Results: Stock surges after US sales, margins beat expectationsThe collaboration is aimed at expanding the reach of tirzepatide beyond cities where Lilly currently has a presence, thereby enhancing access for patients across India.
Achin Gupta, Global Chief Operating Officer, Cipla Ltd, said, “At Cipla, we remain steadfast in our commitment to advancing patient care by facilitating access to the best of global scientific innovation. With the introduction of Yurpeak(tirzepatide), we are stepping into obesity care with the same commitment and scale that have defined our efforts in respiratory and chronic therapies.”
Tirzepatide is the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is a prescription-based medication indicated as an adjunct to diet and exercise for managing type 2 diabetes, as well as for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.Also Read: Cipla Q4 Results: Revenue up 9%, FY25 margin guidance surpassed
Yurpeak (tirzepatide) will be available in the KwikPen presentation, a multi-dose single-patient-use prefilled pen. Each pen contains four fixed doses, administered once weekly. The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg, allowing healthcare professionals to personalise treatment plans to better suit individual patient needs.
Shares of Cipla Ltd ended at ₹1,645.00, down by ₹18.60, or 1.12%, on the BSE.
